Overview

• VistaGen fiscal Q2 net loss widens to $19.4 mln from $13.0 mln year-over-year

• R&D expenses increased to $15.9 mln, driven by PALISADE Program costs

• Company expects PALISADE-3 Phase 3 trial results by year-end

Outlook

• VistaGen expects PALISADE-3 trial results by year-end 2025

• PALISADE-4 trial results anticipated in H1 2026

Result Drivers

• R&D EXPENSES - Increase in R&D expenses driven by higher research, development, and contract manufacturing costs for PALISADE Program

• PHASE 3 TRIALS - Completion of randomized portion of PALISADE-3 Phase 3 trial for social anxiety disorder; results expected by year-end

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 5 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy."

• Wall Street's median 12-month price target for Vistagen Therapeutics Inc is $13.50, about 69.9% above its November 12 closing price of $4.07

Press Release: ID:nBwdKPMqa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)